Get the Stockscreener App
20.59
0.72%
-0.15
After Hours:
20.59
Dianthus Therapeutics Inc Stock (DNTH) Latest News
FY2025 Earnings Forecast for DNTH Issued By Lifesci Capital - MarketBeat
Wedbush Equities Analysts Reduce Earnings Estimates for DNTH - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 3.8%Here's Why - MarketBeat
HC Wainwright Reaffirms "Buy" Rating for Dianthus Therapeutics (NASDAQ:DNTH) - MarketBeat
FY2025 EPS Estimates for DNTH Raised by Cantor Fitzgerald - Defense World
Q1 EPS Estimate for Dianthus Therapeutics Lifted by Analyst - MarketBeat
HC Wainwright Issues Optimistic Outlook for DNTH Earnings - Defense World
Dianthus Therapeutics' (DNTH) Outperform Rating Reiterated at Wedbush - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap DownWhat's Next? - MarketBeat
Dianthus Therapeutics (DNTH) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 5.5%Here's Why - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Issues Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
Research Analysts Set Expectations for DNTH Q1 Earnings - Defense World
HC Wainwright Reaffirms Buy Rating for Dianthus Therapeutics (NASDAQ:DNTH) - Defense World
Guggenheim Reaffirms Buy Rating for Dianthus Therapeutics (NASDAQ:DNTH) - Defense World
Wedbush Reaffirms “Outperform” Rating for Dianthus Therapeutics (NASDAQ:DNTH) - Defense World
Dianthus Therapeutics' (DNTH) "Buy" Rating Reaffirmed at Guggenheim - MarketBeat
We're Not Very Worried About Dianthus Therapeutics' (NASDAQ:DNTH) Cash Burn Rate - Yahoo Finance
Dianthus Therapeutics Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
Dianthus Therapeutics (DNTH) to Release Quarterly Earnings on Thursday - Defense World
Dianthus Therapeutics Reports 2024 Financial Results and Clinical Progress - TipRanks
Stifel maintains Buy rating on Dianthus Therapeutics stock By Investing.com - Investing.com Canada
Dianthus Therapeutics shares fall as Q4 results miss expectations By Investing.com - Investing.com South Africa
Dianthus Therapeutics shares fall as Q4 results miss expectations - Investing.com India
Optimistic Buy Rating for Dianthus Therapeutics Driven by Promising DNTH103 Data and Pipeline Progress - TipRanks
Dianthus Therapeutics: Strong Financials and Promising Clinical Trials Justify Buy Rating - TipRanks
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Rating of “Buy” by Brokerages - Defense World
Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue Estimates - Nasdaq
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results - The Manila Times
Dianthus Therapeutics, Inc. /DE/ SEC 10-K Report - TradingView
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 - Bluefield Daily Telegraph
Dianthus Therapeutics: Promising Growth Potential with Innovative DNTH103 and Strong Financial Position - TipRanks
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Up 8.2%Still a Buy? - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 1-Year LowShould You Sell? - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Position Boosted by Rhumbline Advisers - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 5.3%Should You Sell? - MarketBeat
John King named commercial head at Dianthus - BioCentury
Dianthus Therapeutics appoints John King as CCO By Investing.com - Investing.com Canada
Dianthus Therapeutics Appoints Sujay Kango to Board - TipRanks
Dianthus Therapeutics announces board changes - Investing.com India
Dianthus Therapeutics appoints John King as CCO - Investing.com India
Dianthus Therapeutics announces board changes By Investing.com - Investing.com UK
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):